A Double-Blind, Active-Controlled, Multiple-Ascending Dose Study of Aerosolized RSP-1502 in Subjects With CF and Chronic PA Lung Infection

NCT06016088 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

72

Enrollment

INDUSTRY

Sponsor class

Conditions

Cystic Fibrosis Lung
Respiratory Infections, Recurrent, Chronic
Pseudomonas Aeruginosa

Interventions

DRUG: RSP-1502
DRUG: Tobramycin inhalation solution

Sponsor

Respirion Pharmaceuticals Pty Ltd